Authors discuss briefly the interplay between secreted muscle factors and motor neurons and how together they contribute to disease. They very nicely summarize their recent work with miRNA126-5p and how it could be a potential therapeutic. The authors should discuss the feasibility of this potential
therapeutic in humans in more detail and they should also discuss any potential side effects of increasing the miRNA expression. Additionally, the authors need to pay closer attention to their use of acronyms and ensure that they are properly described in the first appearances in the manuscript and that they are used consistently throughout.
The authors present a succinct review of current data related to how factors secreted by muscles are involved in worsening the degeneration seen in SOD1 mutant axons. The authors go on to discuss their recent findings on how miR126-5p targeted to the gastrocnemius muscle was able to mildly improve symptoms in SOD1 mice and propose this as a future therapeutic strategy. The authors also present a nice summary figure.
The authors may want to discuss in more detail the spatial upregulation and down regulation of miR126-5P in ALS patients, as it was only mentioned in the context of the mouse model. Do expression levels differ in the brain vs the spinal cord vs the muscle? It may also be interesting to discuss other potential therapeutic miRNAs as a means of broadening the treatment scope. Additionally, the authors should discuss the feasibility of this targeted miRNA treatment approach in humans, whether multiple injections would be needed in many muscles of the body to be effective or if there are ways to systemically deliver a targeted approach. The authors also present a one sided argument and do not discuss any potential downfalls to this treatment or potential off target effects by manipulating miRNA levels. Since they are involved in regulating many key pathways, potential side effects should be discussed.
Minor editing of the manuscript should be done as some of the wording is clumsy. Additionally, please ensure that all acronyms and abbreviations are fully described the first time they are used in the manuscript and that they are consistently used. For example, page 2, line 1 uses CM but it is only described later on in the manuscript on page 2, line 37.
